Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia.

Blood advances·2026
Same author

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.

Cells·2026
Same author

The predictive value of lesion density in enhancing multiparametric MRI for detecting clinically significant prostate cancer.

Urologic oncology·2026
Same author

Comparative analysis of apixaban vs. enoxaparin for thromboprophylaxis after radical cystectomy A single-center, observational, before-after study.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

CXCR4-LASP1-G9a-SNAIL axis drives NEPC transdifferentiation via induction of EMT and downregulation of REST.

Cell genomics·2025
Same journal

Escaping the trap.

Nature reviews. Cancer·2026
Same journal

A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.

Nature reviews. Cancer·2026
Same journal

Systemic health impact of cancer-associated extracellular vesicles and particles.

Nature reviews. Cancer·2026
Same journal

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026
Same journal

CLIM-TIME links tumour genetics to spatial immune architecture.

Nature reviews. Cancer·2026
Same journal

Serving sulfur to boost anti-tumour immunity.

Nature reviews. Cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Antisense therapy for cancer.

Martin E Gleave1, Brett P Monia

  • 1The Prostate Centre at Vancouver General Hospital, and Division of Urology, University of British Columbia D9, Canada, V5Z 355. gleave@interchange.ubc.ca

Nature Reviews. Cancer
|May 21, 2005
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotides are a promising cancer therapy, targeting genes resistant to other treatments. Improved modifications enhance their effectiveness and clinical trial results show significant gene suppression.

More Related Videos

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 23, 2026

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer progression and therapeutic resistance are linked to specific molecular mechanisms.
  • Gene targets regulating apoptosis, proliferation, and cell signaling are crucial in cancer.
  • Antisense oligonucleotides (ASOs) offer a novel therapeutic strategy for targeting challenging cancer genes.

Purpose of the Study:

  • To review the current status of antisense oligonucleotide drugs in cancer therapy.
  • To explore the potential clinical applications of ASOs for cancer treatment.
  • To discuss future directions for ASO development in oncology.

Main Methods:

  • Review of recent clinical trials and scientific literature on antisense oligonucleotides in cancer.
  • Analysis of chemical modifications enhancing ASO stability and efficacy.
  • Evaluation of ASO's ability to suppress target gene expression.

Main Results:

  • Antisense oligonucleotides effectively target genes not amenable to small-molecule or antibody inhibition.
  • Chemical modifications improve ASO resistance to degradation, prolong half-life, and optimize scheduling.
  • Clinical trials demonstrate significant suppression of target gene expression by ASOs.

Conclusions:

  • Antisense oligonucleotides represent a viable therapeutic approach for various cancers.
  • Ongoing research and development are expanding the potential of ASOs in clinical oncology.
  • Further investigation into ASO modifications and delivery will enhance their therapeutic impact.